Navigation Links
Valensa International and Parry Nutraceuticals Join Forces in the Global Natural Products Marketplace

ORLANDO, Fla., Nov. 26 /PRNewswire/ -- Valensa International (Orlando, USA) and Parry Nutraceuticals (Division of E.I.D. Parry (India) Ltd., Chennai, India), as part of a growth strategy for both companies, have joined forces to usher in the next generation of high-performance nutritional products from plant-derived sources for the condition-specific dietary supplement, functional food and fortified beverage sectors. EID Parry acquired a 48% strategic stake in U.S. Nutraceuticals doing business as Valensa International. Valensa's "Direct to Marketers" product development and business strategy will be expanded under a new management team led by Valensa's President, Dr. Rudi E. Moerck, which includes executives from both companies. With the Valensa investment, Parry becomes a marketing partner and a strategic source of botanical materials and technology for new and existing Valensa products in the fast-growing areas of Omega-3 Essential Fatty Acids (ALA, EPA and DHA); phycocyanins and carotenoids including astaxanthin, lycopene, lutein, zeaxanthin; and others. The new arrangement will strengthen Valensa's ability to market its science-based products globally. Current areas of co-marketing between the companies include astaxanthin and Valensa's patented SpiruZan(TM), a Spirulina/Astaxanthin product co-launched by the two companies at Natural Products Expo East in Boston and HI Europe in Paris.

According to Dr. Rudi E. Moerck, the companies have the same philosophies on sustainable natural product production and focus on natural ingredients made using environmentally responsible technology such as Valensa's organic-certified supercritical carbon dioxide extraction plant in Florida, USA. "Parry Nutraceuticals shares Valensa International's commitment to creating the highest-quality products based on the best available science for the condition-specific human health and nutrition market," he said. "Parry Nutraceuticals is one of the leading producers of ultra-high-quality raw materials including organic Spirulina and carotenoids like beta carotene, astaxanthin, lutein and tomato lycopene. Our cooperative new product development work with Parry will allow us to accelerate our new product development efforts to deliver some of the most exciting new products to the market," he added.

Two Leaders Working Together

Valensa and Parry recently introduced a new dietary supplement, SpiruZan(TM) -- a synergistic complex of micro-algae-based organic Spirulina and Astaxanthin in a small, easy-to-swallow 500 mg caplet presentation. SpiruZan combines the well-known nutritional properties of organic Spirulina with the superior antioxidant properties of Astaxanthin to deliver a "brain+body" supplement that offers enhanced protection from both dietary and environmental stress factors. SpiruZan is now available, providing 1 mg astaxanthin in an organic Spirulina serving. Spirulina product line extensions are also planned.

Parry Nutraceuticals produces the only GRAS-certified Spirulina that is also certified under USDA NOP, OCIA-IFOAM, Naturland and ECOCERT organic standards. Valensa's ingredients are manufactured using the company's DeepExtract(TM) High Pressure Supercritical CO2 Extraction and O2B(TM) Peroxidation Blocker technology, yielding more of the micronutrients contained in natural botanical materials and protecting both products and people from the problems associated with oxidation and rancidification.

    For further information, contact:

    Dr. Rudi E. Moerck, President
    Voice: 210-632-0695
    Fax: 352-483-2095

This release was issued through eReleases(TM). For more information, visit

SOURCE Valensa International
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Valensa and Parry Nutraceuticals Introduce Organic SpiruZan(TM) Spirulina/Astaxanthin Complex as Lifestyle Support for a Fast-Paced World
2. International Formula Council Statement on Melamine and Infant Formulas
3. Pulmonary Hypertension Treated with Stem Cells : International Medical Team Announces Patient Results in Adult Stem Cell Clinical Study for Pulmonary Hypertension
4. MINRAD International, Inc. Announces Termination of RxElite Holdings Inc. as Anesthetics Distributor for the Human Market in United States
5. Lights Out For Bed Bugs as "BEST YET" Cedar Oil Solution Solves International Bed Bug Dilemma
6. AirMed International wins Air Ambulance of the Year for Second Consecutive Year
7. Med-Emerg International Inc. obtains interim court order for plan of arrangement with AIM Health Group Inc.
8. Permanent International Healthcare Marketplace and Education Center Set to Open in New York City in 2013
9. Epocrates Offers International Market Research Panel
10. Accreditation to the International Standards Organization for Quality Management Granted to First U.S. Lab
11. MINRAD International, Inc. to Discuss Current Business Conditions on Tuesday, November 25, 2008
Post Your Comments:
(Date:12/1/2015)... ... 01, 2015 , ... Florida Hospital Tampa is the first health care provider in ... of Florida. , vBloc® Therapy is a vagal blocking therapy, delivered via the Maestro® System, ... mass index (BMI) of at least 40 to 45 kg, or a BMI of at ...
(Date:12/1/2015)... ... ... Dr. Paul Vitenas, one of the top cosmetic surgeons in Texas ... the Best Single Physician Practice in the nation. Dr. Vitenas and his practice were ... the industry publication. , Dr. Vitenas said he was very honored to receive ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... the 7th Annual 2015 Golden Bridge Business Awards under the New Products and ... zero capex web based sample management software that helps labs organize ...
(Date:12/1/2015)... ... December 01, 2015 , ... For ... mark the film for accurate interpretation by the radiologist. The marking utensils are ... from Sacramento, Calif., has found a way to alleviate this problem. , He ...
(Date:12/1/2015)... ... December 01, 2015 , ... McLean, VA., December ... a fixed price per sprint agile development contract to support the National Geospatial-Intelligence ... five years, provides software engineering, infrastructure, as well as operations and sustainment support ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... , Dec. 1, 2015 Relmada Therapeutics, Inc. (OTCQB: ... of chronic pain, announced today that the company will present ... held December 1-3 at the Luxe Sunset Boulevard Hotel in ... , CEO of Relmada Therapeutics, will present on Thursday, December ... . Please register at least 10 minutes ...
(Date:12/1/2015)... ANGELES , Dec. 1, 2015 CytRx ... development company specializing in oncology, today announced that it ... the company,s pivotal global Phase 3 clinical trial of ... (STS). Enrollment was originally estimated to be completed in Q1 ... being conducted under a Special Protocol Assessment from the ...
(Date:12/1/2015)... CHESTERBROOK, Pa. , Dec. 1, 2015 /PRNewswire/ ... leader, announced the launch of CareFront, a first-of-its-kind ... of patients diagnosed with cancer. Designed to be ... newly diagnosed cancer patients with resources for their ... costs. The program also offers tools to help ...
Breaking Medicine Technology: